clinical trial · NCT06963021
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive DisorderNBI-1065845Placebo
brief summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
started
May 30, 2025
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Apr 15, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol